EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4173	((544/363) or (549/496) or (560/153) or (514/253.08,471,550)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/20 07:30

C:\Program Files\Stnexp\Queries\10511489 (f).str





chain nodes :
1 2 3 5 6 7 8 9 10 11 12 22 23 24 25 28 30
ring nodes :
14 15 16 17 18 19
chain bonds :
1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24 24-25 28-30
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30
exact bonds :
1-22 5-6 5-23 9-10
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

G1:O,S,N

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 29:Atom 30:CLASS

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (e).str





chain nodes :
1 2 3 5 6 7 8 9 10 11 12 22 23 24 25 28 30
ring nodes :
14 15 16 17 18 19
chain bonds :
1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24
24-25 28-30
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30
exact bonds :
1-22 5-6 5-23 9-10
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

G1:O,S,N

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 29:Atom 30:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS

```
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 06:21:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    83331 TO ITERATE

  2.4% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      1649457 TO  1683783
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (f).str
```





```
chain nodes :
1  2  3  5  6  7  8  9  10  11  12  22  23  24  25  28  30
ring nodes :
14  15  16  17  18  19
chain bonds :
1-2  1-3  1-22  3-5  5-6  5-23  6-7  6-8  8-9  9-10  10-11  10-12  12-15  23-24
24-25  28-30
ring bonds :
14-15  14-19  15-16  16-17  17-18  18-19
exact/norm bonds :
1-2  1-3  3-5  6-7  6-8  8-9  10-11  10-12  12-15  23-24  24-25  28-30
exact bonds :
```

```
1-22  5-6  5-23  9-10
normalized bonds :
14-15  14-19  15-16  16-17  17-18  18-19
isolated ring systems :
containing 14 :


G1:O,S,N

Match level :
1:CLASS  2:CLASS  3:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  14:Atom  15:Atom  16:CLASS  17:CLASS  18:Atom  19:Atom
22:CLASS  23:CLASS  24:CLASS  25:CLASS  28:CLASS  29:Atom  30:CLASS



L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam
SAMPLE SEARCH INITIATED 06:23:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    12177 TO ITERATE

 16.4% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       236928 TO   250152
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (g).str
```





chain nodes :
1 2 3 5 6 7 8 9 10 11 12 22 23 24 25 28 30
ring nodes :
14 15 16 17 18 19
chain bonds :
1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24
24-25 28-30
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30
exact bonds :
1-22 5-6 5-23 9-10
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

G1:O,S,N

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 29:Atom 30:CLASS

L5 STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5 STR

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l5 sss sam
SAMPLE SEARCH INITIATED 06:26:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    74935 TO ITERATE

  2.7% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      1482410 TO  1514990
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L5

=> s l3 sss ful
FULL SEARCH INITIATED 06:28:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   243566 TO ITERATE

100.0% PROCESSED   243566 ITERATIONS                           10 ANSWERS
SEARCH TIME: 00.00.04

L7           10 SEA SSS FUL L3

=> => s l7
L8            2 L7

=> d l8 1-2 bib,ab,hitstr
```

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:855762 CAPLUS
DN 139:354460
TI Peptide deformylase activated prodrugs
IN Sergeeva, Maria V.; Doppalapudi, Venkata Ramana
PA Newbiotics, Inc., USA; Celmed Oncology (USA), Inc.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088913	A2	20031030	WO 2003-US11981	20030417
	WO 2003088913	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, RO, SE, SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482029	A1	20031030	CA 2003-2482029	20030417
	AU 2003225047	A1	20031103	AU 2003-225047	20030417
	EP 1499318	A2	20050126	EP 2003-721752	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005096254	A1	20050505	US 2003-511489	20030417
	CN 1662238	A	20050831	CN 2003-813847	20030417
	JP 2006507219	T	20060302	JP 2003-585666	20030417
	BR 2003009418	A	20070306	BR 2003-9418	20030417
	MX 2004PA10230	A	20050608	MX 2004-PA10230	20041015
PRAI	US 2002-374089P	P	20020418		
	WO 2003-US11981	W	20030417		

OS MARPAT 139:354460
AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, and E. cloacae. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.
IT 474780-84-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474780-84-2 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474877-34-4P, NB 3024 474877-35-5P, NB 3057
474877-36-6P, NB 3068 474877-37-7P, NB 3103
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrug; peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474877-34-4 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[(1-oxido-2-pyridinyl)thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474877-35-5 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

SMe

RN 474877-36-6 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 474877-37-7 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[bis(2-chloroethyl)amino]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 618443-15-5P, NB 3144 618443-16-6P, NB 3145
618443-17-7P, NB 3162 618443-18-8P, NB 3165
618443-19-9P, NB 3177
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrugs from; peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 618443-15-5 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 2,6-dibromo-4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618443-16-6 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 5'-(hydroxymethyl)[1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618443-17-7 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 2-bromo-4-(hydroxymethyl)-6-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618443-18-8 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-(hydroxymethyl)-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618443-19-9 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 2-bromo-6-(2-furanyl)-4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


OH
O
Br
O
H
N
HN
S
CHO
O
S
Bu-i
SMe
O

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:868689 CAPLUS
DN 137:358150
TI Peptide deformylase activated prodrugs
IN Sergeeva, Maria Vladimir; Doppalapudi, Venkata Ramana
PA Newbiotics, Inc., USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English

Same Inv Entity

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089739	A2	20021114	WO 2002-US14500	20020509
	WO 2002089739	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2447470	A1	20021114	CA 2002-2447470	20020509
	AU 2002314773	A1	20021118	AU 2002-314773	20020509
	US 2003091587	A1	20030515	US 2002-142089	20020509
	US 7163923	B2	20070116		
	EP 1399467	A2	20040324	EP 2002-741696	20020509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010149	A	20040629	BR 2002-10149	20020509
	JP 2005505502	T	20050224	JP 2002-586878	20020509
PRAI	US 2001-290099P	P	20010509		
	WO 2002-US14500	W	20020509		

OS MARPAT 137:358150

AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae and P. aeruginosa. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase-expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

IT 474877-35-5P, NB 3057 474877-36-6P, NB 3068
474877-37-7P, NB 3103
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-35-5 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

SMe

RN 474877-36-6 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 474877-37-7 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[bis(2-chloroethyl)amino]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474877-34-4P, NB 3024
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474877-34-4 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[(1-oxido-2-pyridinyl)thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474780-84-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474780-84-2 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    11.48     189.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.56      -1.56

STN INTERNATIONAL LOGOFF AT 06:29:47 ON 20 SEP 2007
```

C:\Program Files\Stnexp\Queries\10511489 (d).str



chain nodes :
1 2 3 5 6 7 8 9 10 11 21 22 24 25 26 27 32 34 35 36 37 38 41
ring nodes :
14 15 16 17 18 19
ring/chain nodes :
12
chain bonds :
1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 21-34 22-24 22-41 24-25 25-26 25-27 35-36 37-38
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 21-34 22-24 24-25 25-26 25-27 35-36 37-38
exact bonds :
5-6 9-10 22-41
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 32:CLASS 33:Atom 34:Atom

35:CLASS36:Atom 37:CLASS38:Atom 41:CLASS

=> .....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (b).str





chain nodes :
1 2 3 5 6 7 8 9 10 11 27 28 30 31 32 33 39
ring nodes :
14 15 16 17 18 19 21 22 23 24 25 26
ring/chain nodes :
12
chain bonds :
1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 22-27 28-30 30-31
31-32 31-33
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 22-27 28-30 30-31 31-32
31-33
exact bonds :
5-6 9-10

```
normalized bonds :
14-15  14-19  15-16  16-17  17-18  18-19  21-22  21-26  22-23  23-24  24-25  25-26
isolated ring systems :
containing 14 : 21 :


G1:O,S

G2:[*1],[*2]

Match level :
1:CLASS  2:CLASS  3:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  14:Atom  15:Atom  16:CLASS  17:CLASS  18:Atom  19:Atom  21:Atom
 22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:CLASS  30:CLASS
31:CLASS  32:CLASS  33:Atom  39:CLASS  40:Atom



L3      STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1              SCR 1839
L2              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L4              QUE  L3 AND L1 NOT L2


=> s l4 sss sam
SAMPLE SEARCH INITIATED 18:32:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      604 TO ITERATE

100.0% PROCESSED      604 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        10606 TO    13554
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L3 AND L1 NOT L2

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (c).str
```





chain nodes :
1 2 3 5 6 7 8 9 10 11 21 22 24 25 26 27 33 35 36 37 38 39
ring nodes :
14 15 16 17 18 19
ring/chain nodes :
12
chain bonds :
1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 21-35 22-24 24-25
25-26 25-27 36-37 38-39
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 21-35 22-24 24-25 25-26
25-27 36-37 38-39
exact bonds :
5-6 9-10
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 33:CLASS 34:Atom
35:Atom 36:CLASS 37:Atom 38:CLASS 39:Atom

```
L6      STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l6 sss sam
SAMPLE SEARCH INITIATED 18:34:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      811 TO ITERATE

100.0% PROCESSED      811 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        14512 TO    17928
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (d).str
```



```
chain nodes :
1  2  3  5  6  7  8  9  10  11  21  22  24  25  26  27  32  34  35  36  37  38  41
ring nodes :
14  15  16  17  18  19
ring/chain nodes :
12
chain bonds :
1-2  1-3  3-5  5-6  6-7  6-8  8-9  9-10  10-11  10-12  12-15  21-34  22-24  22-41
24-25  25-26  25-27  35-36  37-38
ring bonds :
14-15  14-19  15-16  16-17  17-18  18-19
exact/norm bonds :
1-2  1-3  3-5  6-7  6-8  8-9  10-11  10-12  12-15  21-34  22-24  24-25  25-26
25-27  35-36  37-38
exact bonds :
5-6  9-10  22-41
normalized bonds :
14-15  14-19  15-16  16-17  17-18  18-19
isolated ring systems :
containing 14 :


G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :
1:CLASS  2:CLASS  3:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  14:Atom  15:Atom  16:CLASS  17:CLASS  18:Atom  19:Atom
21:CLASS  22:CLASS  24:CLASS  25:CLASS  26:CLASS  27:Atom  32:CLASS  33:Atom
34:Atom  35:CLASS  36:Atom  37:CLASS  38:Atom  41:CLASS



L8      STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l8 sss sam
SAMPLE SEARCH INITIATED 18:37:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      811 TO ITERATE

100.0% PROCESSED      811 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        14512 TO    17928
PROJECTED ANSWERS:               0 TO        0

L9            0 SEA SSS SAM L8
```

```
=> s l8 sss ful
FULL SEARCH INITIATED 18:37:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    15839 TO ITERATE

100.0% PROCESSED    15839 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.02

L10            5 SEA SSS FUL L8

=> => s l10
L11            3 L10

=> d l11 1-3 bib,ab,hitstr
```

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:855762 CAPLUS
DN 139:354460
TI Peptide deformylase activated prodrugs
IN Sergeeva, Maria V.; Doppalapudi, Venkata Ramana
PA Newbiotics, Inc., USA; Celmed Oncology (USA), Inc.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088913	A2	20031030	WO 2003-US11981	20030417
	WO 2003088913	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, RO, SE, SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482029	A1	20031030	CA 2003-2482029	20030417
	AU 2003225047	A1	20031103	AU 2003-225047	20030417
	EP 1499318	A2	20050126	EP 2003-721752	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005096254	A1	20050505	US 2003-511489	20030417
	CN 1662238	A	20050831	CN 2003-813847	20030417
	JP 2006507219	T	20060302	JP 2003-585666	20030417
	BR 2003009418	A	20070306	BR 2003-9418	20030417
	MX 2004PA10230	A	20050608	MX 2004-PA10230	20041015
PRAI	US 2002-374089P	P	20020418		
	WO 2003-US11981	W	20030417		

OS MARPAT 139:354460
AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, and E. cloacae. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.
IT 474877-34-4P, NB 3024 474877-35-5P, NB 3057
474877-36-6P, NB 3068
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrug; peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474877-34-4 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[(1-oxido-2-pyridinyl)thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474877-35-5 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

SMe

RN 474877-36-6 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 474877-33-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrugs; peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474877-33-3 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 5-chloro-2-(2,4-dichlorophenoxy)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:868689 CAPLUS
DN 137:358150
TI Peptide deformylase activated prodrugs
IN Sergeeva, Maria Vladimir; Doppalapudi, Venkata Ramana
PA Newbiotics, Inc., USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English

Same Inv.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089739	A2	20021114	WO 2002-US14500	20020509
	WO 2002089739	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2447470	A1	20021114	CA 2002-2447470	20020509
	AU 2002314773	A1	20021118	AU 2002-314773	20020509
	US 2003091587	A1	20030515	US 2002-142089	20020509
	US 7163923	B2	20070116		
	EP 1399467	A2	20040324	EP 2002-741696	20020509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010149	A	20040629	BR 2002-10149	20020509
	JP 2005505502	T	20050224	JP 2002-586878	20020509
PRAI	US 2001-290099P	P	20010509		
	WO 2002-US14500	W	20020509		

OS MARPAT 137:358150

AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae and P. aeruginosa. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase-expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

IT 474877-33-3P, NB 2046 474877-35-5P, NB 3057
474877-36-6P, NB 3068
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-33-3 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 5-chloro-2-(2,4-dichlorophenoxy)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474877-35-5 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

SMe

RN 474877-36-6 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 474877-34-4P, NB 3024
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide deformylase activated prodrugs for inhibiting growth of microorganism)
RN 474877-34-4 CAPLUS
CN L-Leucine, N-formyl-L-methionyl-, 4-[[(1-oxido-2-pyridinyl)thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


O
N
S
O
OHC
i-Bu
S
NH
O
NH
MeS
S
O

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1982:104773 CAPLUS
DN 96:104773
TI Amino acid and peptide ester of leucoindoanilines and an agent containing this compound for determining a proteolytic enzyme
IN Berger, Dieter; Braun, Franz; Frey, Guenter; Knappe, Wolfgang Reinhold; Kuhr, Manfred; Werner, Wolfgang
PA Boehringer Mannheim G.m.b.H. , Fed. Rep. Ger.
SO Ger. Offen., 60 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3005845	A1	19810903	DE 1980-3005845	19800216
	US 4469789	A	19840904	US 1981-229205	19810128
	EP 34323	A2	19810826	EP 1981-100909	19810210
	EP 34323	A3	19811230		
	EP 34323	B1	19830817		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AT 4453	T	19830915	AT 1981-100909	19810210
	JP 56138153	A	19811028	JP 1981-20251	19810216
	JP 02051900	B	19901108		
PRAI	DE 1980-3005845	A	19800216		
	EP 1981-100909	A	19810210		

AB Title esters I [X = amino acid or peptide residue; R = N-protective group; R1, R2, R3, R4 = H, perhaloalkyl, alkoxy, aralkoxy, acylamino, acylalkenyl, OH, alkylmercapto, alkylsulfonyl, COR11 (R11 = OH, alkoxy, aralkoxy, NH2, alkylamino); R5, R6, R7, R8 = H, halo, perhaloalkyl, alkoxy, aralkoxy, OH, NO2; R9, R10 = H, alkyl, hydroxyalkyl; R9R10 = alkylene, alkyleneoxyalkylene] were prepared as substrates for proteolytic enzymes. The determination of proteinases or esterases can be achieved by enzymically cleaving I to the corresponding phenols II, which can be oxidized to the colored cyclohexadienones III. Thus, Tos-Ala-OH (Tos = tosyl) was treated SOCl2 to give the acid chloride, which was esterified with 4-hydroxy-4'-(dimethylamino)diphenylamine to give 13.6% ester IV. A solution of 45.3 mg IV in 100 mL acetone was used for enzyme determination of leukocyte-containing urine.

IT 80898-53-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 80898-53-9 CAPLUS
CN L-Alanine, N-[N-[N-[(4-methylphenyl)sulfonyl]-L-alanyl]-L-alanyl]-, 4-[[4-(dimethylamino)phenyl]amino]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




Me

```
=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                16.28     193.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -2.34      -2.34

STN INTERNATIONAL LOGOFF AT 18:38:31 ON 19 SEP 2007
```